Systematic Review: The Trousseau Syndrome Revisited: Should We Screen Extensively for Cancer in Patients with Venous Thromboembolism?
- 2 September 2008
- journal article
- review article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 149 (5) , 323-333
Abstract
Identifying previously undiagnosed cancer in patients with newly diagnosed venous thromboembolism (VTE) is important. Screening for malignant conditions can potentially diagnose more cases of cancer and at earlier stages, thereby preventing cancer-associated morbidity and perhaps mortality. To summarize the period prevalence of previously undiagnosed cancer at baseline (within 1 month of VTE diagnosis), 6 months, and 12 months after VTE diagnosis and to quantify the additional value of an extensive cancer screening strategy (limited screening plus imaging techniques or tumor marker measurement) at baseline compared with more limited screening (history, physical examination, and simple widely available tests) at baseline. MEDLINE, EMBASE, the Cochrane Register of Controlled Trials, and Evidence-Based Medicine Reviews. A total of 36 studies that reported the prevalence of undiagnosed cancer at baseline, 6 months, and 12 months were selected. Fourteen articles and 1 abstract also met inclusion criteria for the assessment of extensive versus limited cancer screening. Two reviewers independently extracted data onto standardized forms. The period prevalence of previously undiagnosed cancer in patients with unprovoked VTE was 6.1% (95% CI, 5.0% to 7.1%) at baseline and 10.0% (CI, 8.6% to 11.3%) from baseline to 12 months. An extensive screening strategy using computed tomography of the abdomen and pelvis statistically significantly increased the proportion of previously undiagnosed cancer detected from 49.4% (CI, 40.2% to 58.5%) (with limited screening alone) to 69.7% (CI, 61.1% to 77.8%) in patients with unprovoked VTE. The investigators could not determine complication rates, cost-effectiveness, and difference in morbidity and mortality associated with extensive screening strategies. Previously undiagnosed cancer is frequent in patients with unprovoked VTE. Many cases of previously undiagnosed cancer are missed by screening. An extensive cancer screening strategy detects more malignant conditions than does a limited screening strategy.Keywords
This publication has 44 references indexed in Scilit:
- American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With CancerJournal of Clinical Oncology, 2007
- The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trialsJournal of Thrombosis and Haemostasis, 2007
- Incidence of Venous Thromboembolism in the Year Before the Diagnosis of Cancer in 528 693 AdultsArchives of internal medicine (1960), 2005
- Randomized Comparison of Low Molecular Weight Heparin and Coumarin Derivatives on the Survival of Patients With Cancer and Venous ThromboembolismJournal of Clinical Oncology, 2005
- Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolismJournal of Thrombosis and Haemostasis, 2004
- Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trialJournal of Thrombosis and Haemostasis, 2004
- Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with CancerNew England Journal of Medicine, 2003
- Venous Thromboembolism and Cancer: Risks and OutcomesCirculation, 2003
- The Risk of a Diagnosis of Cancer after Primary Deep Venous Thrombosis or Pulmonary EmbolismNew England Journal of Medicine, 1998
- Deep venous thrombosis and occult malignancy: an epidemiological studyBMJ, 1994